Moderna Shares Surge 12% on Reports of Potential Acquisition or Partnership Talks
核心洞察
Moderna stock jumped as much as 12% following reports that the company is in discussions with at least one large pharmaceutical company about a potential deal of significant scope.
The nature of the potential agreement remains unclear, with both a full acquisition and a large partnership being considered as possible options.
Bloomberg Intelligence analysts suggest a partnership for Moderna's vaccine business or cancer (搜索) portfolio is more likely than a full takeover, given existing partnerships.
Moderna shares surged as much as 12% Thursday following reports that the COVID-19 (搜索) vaccine maker is engaged in discussions with at least one major pharmaceutical company regarding "a deal of significant scope," according to STAT News.
The report, citing a person familiar with the discussions, indicated that the nature of the potential agreement remains unclear, with both a buyout and a large partnership being considered as options. Moderna declined to comment on the reported deal talks.
Market Response and Stock Performance
Moderna's stock rose 11.7% to $27.56 during trading, providing a rare bright spot for investors who have watched the company's shares lose over 90% from their pandemic-era highs. The vaccine maker's stock has been battered by declining COVID revenue and political concerns related to changes in U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic. Including the session gains, the stock remains down approximately 37% year-to-date.
Strategic Diversification Efforts
The Cambridge, Massachusetts-based biotech company has been actively seeking to diversify beyond its COVID-19 (搜索) vaccine business as pandemic-related demand has waned. Moderna shares had fallen more than 40% over the past year prior to Thursday's surge, reflecting investor concerns about the company's post-pandemic strategy.
"In unprecedented circumstances, we made a deliberate choice to reinvest in research and development — bringing three products to approval in 2025 alone and advancing a diverse pipeline, including an expanding oncology portfolio," said Moderna spokesperson Chris Ridley in a statement.
Analyst Perspectives on Potential Deal Structure
Bloomberg Intelligence analysts Sam Fazeli and Max Nisenwrit expressed skepticism about the likelihood of a full takeover. "A full takeover is unlikely, given that the company's key non-vaccine asset (mRNA-4157) is already partnered with Merck (搜索)," the analysts noted.
Instead, they suggested that finding a partner for Moderna's vaccine business or emerging cancer (搜索) portfolio is more probable and "would help alleviate the company's cash burn." This strategic approach could provide the financial stability and resources needed to support Moderna's diversification efforts while maintaining its independence in key therapeutic areas.